Welcome to 3i

For US regulatory reasons, US Residents are not to enter this site without the express permission of 3i Group plc, and 3i Group plc is not offering any securities or services in the United States or to US Residents through this site. (The term "US Residents" is defined in the detailed terms and conditions set out in the Terms and conditions page).

I am not a US resident (or I am, but I have 3i Group plc's express permission to use this site) and I accept the terms and conditions.

Terms and conditions

27 Oct 2005

3i backs management in 48.5m buyout of Panreac

  • Private Equity
3i, Europe's leading private equity company, today announces that it has supported the management of Panreac Quimica S.A., a leading Spanish manufacturer and supplier of quality chemicals for laboratory research and production, in a €48.5m buyout.

Mark Heappey, 3i MD Spain, commented on the investment rational: "Panreac is run by a top class management team, led by Joan Roget, who has been an impressive driver of growth and profitability over the last few years. Given the market opportunities internationally, we are delighted to work with Joan and the rest of his team in realising their vision."

3i''s investment will enable the company to maintain its market leading brand in analytical reagents in Spain, continue to grow organically through product diversification, and put in place plans for international expansion; particularly in Germany, France and Italy. 

Panreac, based in Barcelona, is a leader in the manufacture of reagents for analysis and pure chemical agents. The products, including ACS reagents, high purity solvents for HPLC, fine chemicals, food chemicals, culture media for microbiology, products for histology are mainly applied in the Pharma industry (23%), hospitals and universities (36%), food industry (17%), chemical industry (16%) and various other

industries (8%). A family-owned business since its inception in 1945, the company has gone from strength to strength, now enjoying a 35% market share of the niche chemical sector in Spain and a turnover of €30m. In 1998, Alexander Esteban, the son of the company''s founder, invited private equity company Bridgepoint to invest in the company.

Notes to editors

About 3i
3i is a world leader in private equity and venture capital.  We focus on buyouts, growth capital and venture capital and invest across Europe, in the United States and Asia.

Our competitive advantage comes from our international network and the strength and breadth of our relationships in business.  These underpin the value that we deliver to our portfolio and to our shareholders.  www.3i.com

3i Buyout Business
The 3i European Buyout Business is a leader in the European mid-market. 3i lead mid-market buyouts up to €1bn using insight from local knowledge, international connections, and sector teams. Managing €5bn and invested in 100 companies across Europe, the business invests in all sectors, with a particular focus on media, healthcare and business support services. Recent investments include NCP - UK - £550m - parking services and traffic management, Keolis - France - €540m - passenger transport, Betapharm - Germany - €300m - pharmaceuticals. Recent successful exits include Westminster Healthcare - UK - €751m, Travelex - UK - foreign exchange services - £1bn, YBR Group - directories - €1.8bn - Local Press - newspaper publishers - £65m.